



TEXAS Cancer Clinic

36

PR 35
(73FR45635)

DOCKETED
USNRC

November 5, 2008 (11:42am)

OFFICE OF SECRETARY
RULEMAKINGS AND
ADJUDICATIONS STAFF

October 27, 2008

Annette L. Vietti-Cook
Secretary of the Commission
U.S. Nuclear Regulatory Commission
Washington, DC 20555-0001

ATTN: Rulemakings and Adjudications Staff

RE: Comments on Proposed Rule for Medical Use of Byproduct Material—
Amendments/Medical Event Definitions (RIN 3150-AI26, NRC-2008-0071) [See
73 FR 45635 (August 6, 2008)]

Dear Ms. Vietti-Cook:

I am a radiation oncologist and operate out of my own freestanding cancer center in San Antonio, Texas called the Texas Cancer Clinic. The clinic is only four years old, but my practice has focused primarily on various forms of brachytherapy for 19 years in a University, military and now private practice environment. I am a board member for the American Brachytherapy Society and have published and lectured widely in the brachytherapy field.

I am writing because of my concern that the U.S. Nuclear Regulatory Commission's (NRC's) proposed modifications to 10 CFR 35.40 and 35.3045 to establish separate medical event criteria and written directive requirements for permanent implant brachytherapy would result in inappropriately categorizing some medically acceptable implants as "medical events" (ME's). Although I understand and appreciate the efforts to better define medical event criteria, I am afraid that the proposed changes are not practical and would place many physicians, including experts, open for scrutiny for many circumstances that occur relatively frequently due to the nature of these procedures.

1. TIMING OF WRITTEN DIRECTIVE AND MEDICAL EVENTS

The proposed rule language for § 35.40(b)(6) and § 35.3045(a)(2) does not take into account clinical practice realities. Many authorized users (AUs), including myself, perform real-time, adaptive, interactive planning, whereby the written directive and the source strength to be implanted are based on the actual volume dynamically determined during the procedure rather than based on the pre-implant volume.

9102 Floyd Curl
San Antonio, Texas 78240
210-247-0888
Fax: 210-558-0758
www.texasccancerclinic.com

Template=SECY-067

SECY-02

Radiation Oncology

Bradley R. Prestidge, M.D.,
President/CEO/Medical Director

Suresh V. Dutta, M.D.

Sylvia G. Zubyk, M.D.

Surgical Oncology

Genetic Counseling

Alexander R. Miller, M.D., F.A.C.S.

Jill M. Cortada, M.S.N., R.N.

Physics

Amir Sadeghi, Ph.D., DABR,
Chief Medical Physicist

Ramiro Pino, Ph.D.

Physician Assistant

Sheila B. Pinkson, MPAS, P.A.-C

Real-time planning is a more contemporary method of implantation. It allows the physician to take into account any alterations in the organ volume and shape that occur between the time of the pre-plan and the implant procedure and therefore represents the actual organ volume and implant situation. For those performing real-time adaptive planning implantation, the total source strength to be implanted is determined intraoperatively during the implantation procedure and not pre-implant.

I support **ASTRO's suggested revisions** to the proposed regulations. I believe this modification will clarify that the source strength implanted as stated in the WD refers to the source strength implanted after administration but before the patient leaves the post-treatment recovery area.

2. DEFINITION OF TREATMENT SITE

The definition of "treatment site" described in § 35.2 as "the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive" leads to some ambiguity regarding the exact volume that "treatment site" refers to in § 35.3045(a)(2)(ii). There are various standard volumes already defined in radiation oncology, including the gross tumor volume, which is the volume that contains tumor. Two other margins are added to the gross tumor volume during the brachytherapy planning process. One margin is added to account for the subclinical spread of the tumor, which is termed the "clinical target volume," and a second margin is added to account for uncertainties in source positioning, tumor boundaries, isodose constrictions, etc., which is termed the "planning target volume."

These expansion margins are not constant but change for different clinical situations. Radiation oncologists use a larger margin if there is high degree of uncertainty and/or if there are no adjacent critical structures. Conversely, the margins are smaller if the boundary is distinct and/or if there are adjacent critical structures.

I believe that the proposed regulations cross into clinical decision-making by specifying margin parameters and the source strength to be placed in the margin. The NRC will be interfering into medical judgment if it dictates the amount of source strength the authorized user can place in the margins. Using the definition found at § 35.2 of "treatment site" as "the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive" raises ambiguities in terms of the proposed medical event reports and notifications as it is unclear whether the "treatment site" refers to the gross tumor volume or includes the margins in the clinical target volume or those in the planning target volume.


I support **ASTRO's recommended changes to the definition of "treatment site" at § 35.2 be revised to reflect the distinct clinical areas - gross tumor, the clinical target volume, plus a variable planning target volume.**

Further, by following ASTRO's suggested alternative language, section § 35.3045 (a)(2)(iii) of the proposed rule would become superfluous and therefore could be eliminated.

I believe that these suggested modifications to the proposed rule language are necessary because in the normal course of some medically acceptable brachytherapy implant procedures, a few seeds may come to rest beyond 3 cm (1.2 in) from the outside boundary of the treatment site. This naturally occurs in the case of prostate brachytherapy for example, because radioactive sources shift and sometimes migrate from their intended position through no fault of the brachytherapist. These sorts of routine events have not been shown to be associated with adverse outcomes and therefore should not be considered ME's.

Thank you for giving me this opportunity to provide comments on the NRC's proposed rule changes to 10 CFR 35.40 and 35.3045 related to medical events in permanent implant brachytherapy. Please contact me at (210) 247-0860 if you have any questions.

Sincerely,



Bradley R. Prestidge, M.D.
President/CEO/Medical Director
Texas Cancer Clinic